Role of COVID-19 Vaccine in the Management of Gynecologic Oncology Lymphadenopathies

Laura Fernandez Sanahuja, Ester Miralpeix, Josep Maria Solé Sedeño, Marta Baucells, Berta Fabregó, Ana Sierra and Gemma Mancebo ()
Additional contact information
Laura Fernandez Sanahuja: Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain
Ester Miralpeix: Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain
Josep Maria Solé Sedeño: Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain
Marta Baucells: Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain
Berta Fabregó: Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain
Ana Sierra: Department of Radiology, Hospital del Mar, 08003 Barcelona, Spain
Gemma Mancebo: Department of Obstetrics and Gynecology, Hospital del Mar, 08003 Barcelona, Spain

IJERPH, 2024, vol. 21, issue 8, 1-10

Abstract: Background: This study aimed to evaluate the incidence of lymphadenopathies after COVID-19 vaccination and their impact on the clinical management of gynecologic oncology patients. Methods: A retrospective observational study was conducted involving patients who underwent abdominopelvic or thoracoabdominopelvic CT scans during diagnosis or follow-up. Patients were classified into a vaccinated group (Vac group) and a non-vaccinated group (NoVac group). The radiological appearance of lymphadenopathies was categorized as low or high risk of malignancy, and management strategies were recorded as standard management or additional assessment. Results: 75 patients were included, with 44 in the Vac group and 31 in the NoVac group. The incidence of lymphadenopathies was similar between the groups: 34.1% in the Vac group and 32.3% in the NoVac group ( p = 0.868). High-risk lymphadenopathies were observed in 20.4% of the Vac group and 22.6% of the NoVac group, while low-risk lymphadenopathies were seen in 13.6% of the Vac group and 9.7% of the NoVac group ( p = 0.691). Standard management was the most common approach, used in 80.0% of the Vac group and 100.0% of the NoVac group ( p = 0.25). Conclusions: COVID-19 vaccine does not increase the incidence of lymphadenopathies in imaging tests of gynecological cancer patients.

Keywords: COVID-19; vaccination; gynecological cancer; lymphadenopathies (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/21/8/1063/pdf (application/pdf)
https://www.mdpi.com/1660-4601/21/8/1063/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:21:y:2024:i:8:p:1063-:d:1455727

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().